**Evidence Table 5. Benefits (KQ 1 & 2)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Ahrens, 20021  NA | NA | NR | PSS-SR (range: NR), Mean  Difference Pretreatment  G1: 16.89 (SD=10.49)  G2: 19.36 (SD=10.12)  Within group change:  G1: -9.07 (calculated)  G2: 1.02 (calculated)  Between group change: -10.09 (calculated)  ANOVA (1, 36)=19.44, p=0.0001  IES (range: NR), Mean  Difference  Pretreatment  G1: 35.52 (SD=11.80)  G2: 33.42 (SD=8.70)  Within group change:  G1: -12.11 (calculated)  G2: 2.08 (calculated)  Between group change: -14.19 (calculated)  ANOVA (1, 36)=20.49, p=0.0001 | BDI (range: NR), Mean difference Pretreatment  G1: 15.26 (SD=12.10)  G2: 18.52 (SD=9.97)  Within group change:  G1: -8.38 (calculated)  G2: -0.58 (calculated)  Between group change (95% CI): -7.80 (calculated)  ANOVA (1, 36)=17.95, p=0.02 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Berger, 20072  NA | UPID-Severity (range: 0-68):  Pretreatment  G1: 25.6 (SD=12.3)  G2: 23.5 (SD=11.2)  Within group change at post-treatment:  G1: -11.7 (calculated)  G2: 0.4 (calculated)  Between group change at post-treatment: -12.1 (calculated)  Between group ANOVA: F=129.33, df=1,140, p<0.001  Symptoms (range: 0-17):  Pretreatment  G1: 7.6 (SD=3.9)  G2: 6.7 (SD=3.8)  Within group change at post-treatment:  G1: -3.7 (calculated)  G2: 0.9 (calculated)  Between group change at post-treatment: -4.6 (calculated)  Between group ANOVA: F=132.62, df=1,140, p<0.001 | UPID-Diagnosis  Pretreatment  G1: 8.6% (calculated)  G2: 6.9% (calculated)  Within group change in proportion with PTSD at post-treatment  G1: -8.6% (calculated)  G2: 0%  Between group change in PTSD diagnosis proportion at post-treatment: -8.6%  Significance not reported | NA | SCARED, Generalized Anxiety, Mean Generalized anxiety (range: 8-24):  Pretreatment  G1: 12.5 (SD=2.9)  G2: 12.4 (SD=3.1)  Within group change at post-treatment:  G1: -2.3 (calculated)  G2: 0.5 (calculated)  Between group change at post-treatment: -2.8 (calculated)  Between group ANOVA: F=59.25, df=1,140, p<0.001  Separation anxiety (range: 7-21):  Pretreatment  G1: 14.8 (SD=4.3)  G2: 14.3 (SD=3.7)  Within group change at post-treatment:  G1: -2.6 (calculated)  G2: -0.2 (calculated)  Between group change at post-treatment: -2.4 (calculated)  Between group ANOVA: F=29.24, df=1,140, p<0.001 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Berger, 20093  ES-SL | UPID (range: 0-68), Mean Pretreatment  G1: 44.94 (SD=8.7)  G2: 47.23 (SD=7.2)  Within group change at post-treatment:  G1: -8.73 (calculated)  G2: -1.52 (calculated)  Between group change at post-treatment: -7.21 (calculated)  Between group ANOVA: F=53.52, df=1,164, p<0.001 | Categorical measure of probable PTSD was constructed by assessing whether reported symptoms met criteria for DSM-IV PTSD Dx, Mean Probably PTSD Pretreatment  G1: 28% (SD=33.3%)  G2: 26% (31.7%)  Within group change at post-treatment:  G1: -27.3% (calculated)  G2: -2.6% (calculated)  Between group change at post-treatment: -24.7% (calculated)  Between group chi-square: X2=14.02, df=2, p=0.001 | NA | Brief BDI (range: 0-21), Mean  Pretreatment  G1: 4.44 (SD=3.2)  G2: 4.04 (SD=3.3)  Within group change at post-treatment:  G1: -1.89 (calculated)  G2: -0.34 (calculated)  Between group change at post-treatment: -1.55 (calculated)  Between group ANOVA: F=22.55, df=1,164, p<0.001 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Berkowitz, 20114  NA | UPID (range: NR) full or partial diagnosis  3 Mos. followup  Treatment variable OR (95% CI)): 0.268 (0.10, 0.71), p<0.01 TSCC Post Traumatic Stress Index Scale (range: NR):  Pretreatment  G1: 53.30 (SD=1.34) G2: 51.74 (SD=1.29) Within group change at post-treatment assessment:  G1: -10.33 (calculated)  G2: -5.62 (calculated)  Within group change at 3 Mos.:  G1: -13.56 (calculated)  G2: -9.52 (calculated)  Between group change at post-treatment assessment:  -4.71 (calculated)  Between group change at 3 Mos. assessment: -4.04 (calculated)  Repeated measures with mixed effect models: F=3.25, df=163, p=0.04 | NR | NA | TSCC-Dissociation Index (range: NR) Pretreatment  G1: 47.64 (SD=1.12) G2: 48.23 (SD=1.07) Within group change at post-treatment assessment:  G1: -5.38 (calculated)  G2: -3.11 (calculated)  Within group change at 3 Mos.:  G1: -6.62 (calculated)  G2: -4.69 (calculated)  Between group change at post-treatment assessment: -2.27(calculated)  Between group change at 3 Mos. assessment: -1.95 (calculated)  Repeated measures with mixed effect models: F=1.28, df=163, p=0.28  TSCC Anxiety Index (range: NR):  Pretreatment  G1: 51.34 (SD=1.33) G2: 50.45 (SD=1.29) Within group change at post-treatment assessment:  G1: -10.48 (calculated)  G2: -4.96 (calculated)  Within group change at 3 Mos:  G1: -11.70 (calculated)  G2: -8.63 (calculated)  Between group change at post-treatment assessment: -5.52 (calculated)  Between group change at 3 Mos. assessment: -3.07 (calculated)  Repeated measures with mixed effect models: F=4.89, df=163, p=0.009 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Catani, 20095  NA | NA | UCLA PTSD Diagnosis  Pretreatment  G1: 100% G2: 100% Within group change in proportion at post-treatment assessment:  G1: -75%  G2: -66.6%  Within group change in proportion at 6 Mos.:  G1: -81.3%  G2: -71.4%  Between group change at post-treatment assessment:  8.4% (calculated)  X2 difference p=NS  Between group change at 6 Mos. assessment: -9.9%  X2 difference p=NS | UCLA PTSD Symptoms (range: 0-80), Pretreatment  G1: 37.94 (SD=14.8) G2: 36.58 (SD=14.9) Within group change at post-treatment assessment:  G1: -25.53 (calculated)  G2: -23.99 (calculated)  Within group change at 6 Mos.:  G1: -26.63 (calculated)  G2: -26.83 (calculated)  Between group change at post-treatment assessment:  -1.54 (calculated)  Between group change at 6 Mos. assessment: 0.20 (calculated)  Repeated measures ANOVA for time\*treatment interaction p=0.9 | NR |
| Ford, 20126  TARGET | NA | CAPS-CA (range: NR), B Symptoms, Mean  Pretreatment: G1: 19.4 (SD=9.2) G2: 13.3 (SD=3.8)  Within group change at post-treatment assessment:  G1: -8.7 (SD=8.6) d=1.01  G2: -4.6 (SD=4.8) d=0.95 Between group change at post-treatment assessment: -4.1 (SD=6.4); 95% CI (calculated)  -0.22, 8.42; d=0.64 CAPS-CA, C Symptoms, Mean  Pretreatment:  G1: 22.5 (SD=8.0)  G2: 18.8 (SD=5.9)  Within group change at post-treatment assessment:  G1: -8.5 (SD=8.2) d=1.04  G2: -4.9 (SD=6.6) d=0.75 | NA | TSCC (range: NR), Anxiety. Mean  Pretreatment:  G1: 7.2 (SD=3.6)  G2: 6.8 (SD=4.5)  Within group change at post-treatment assessment:  G1: -2.4 (SD=3.9) d=0.61  G2: -1.3 (SD=4.7) d=0.27  Between group change at post-treatment assessment: -1.2 (SD=3.6); 95% CI (calculated) -1.46, 3.66; d=0.32 TSCC, Depression, Mean  Pretreatment:  G1: 7.4 (SD=3.7)  G2: 6.9 (SD=4.1)  Within group change at post-treatment assessment:  G1:-2.3 (SD=3.6) d=0.65  G2: -2.6 (SD=4.0) d=0.65  Between group change at post-treatment assessment: 0.3 (SD=3.6); 95% CI |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Ford, 20126  TARGET (continued) |  | Between group change at post-treatment assessment: -3.5 (SD=8.4), 95% CI (calculated)  -0.93, 8.13; d=0.42 CAPS-CA, D Symptoms, Mean  Pretreatment:  G1: 17.4 (SD=8.2)  G2: 15.4 (SD=6.3)  Within group change at post-treatment assessment:  G1: -7.4 (SD=7.4) d=0.99 G2: -7.4 (SD=6.1) d=1.23 Between group change at post-treatment assessment: 0.02 (SD=7.5); 95% CI (calculated)  -4.12, 4.12; d=0.00 CAPS-CA, Total Score: Mean  Pretreatment:  G1: 58.9 (SD=20.7)  G2: 47.5 (SD=10.6) Within group change at post-treatment assessment:  G1: -24.4 (SD=19.5) d=1.26 G2: -17.0 (SD=12.6) d=1.35 Between group change at post-treatment assessment: -7.4 (SD=14.1); 95% CI (calculated)  -16.96, 2.16; d=0.53  PTCI, Mean  Pretreatment:  G1: 108.2 (SD=32)  G2: 104.6 (SD=33)  Within group change at post-treatment assessment:  G1: -17.9 (SD=33.6) d=0.53  G2: -10.6 (SD=33.4) d=0.32  Between group change at post-treatment assessment: 7.2 (SD=34.3); 95% CI (calculated)  -12.79, 27.39; d=0.21 |  | (calculated) -2.56, 1.96; d=-0.10 TSCC, Anger, Mean  Pretreatment:  G1: 8.8 (SD=7.1)  G2: 8.3 (SD=6.0)  Within group change at post-treatment assessment:  G1: -1.0 (SD=7.4) d=0.13  G2: -2.5 (SD=5.4) d=0.46  Between group change at post-treatment assessment: 1.5 (SD=4.9); 95% CI (calculated) -5.46, 2.46; d=-0.30 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Gelkopf, 20097  ERASE-Stress | UPID, PTSD Severity, Mean  Pretreatment  G1: 23.6 (SD=9.3)  G2: 20.4 (SD=10.3)  Within group change at post-treatment:  G1: -10.9 (calculated)  G2: -1.9 (calculated)  Between group change at post-treatment: -9.0 (calculated)  Between group ANOVA: F=49.42, df=1,106, p<0.001 | UPID (range: 0-68), PTSD Diagnosis  Pretreatment  G1: 5.2% (calculated)  G2: 0% (calculated)  Within group change at post-treatment:  G1: -5.2% (calculated)  G2: 6.1% (calculated)  Between group change at post-treatment: -11.3% (calculated)  p=NR | NA | Depression  Brief BDI (range: 0-21), Mean  Pretreatment  G1: 3.1 (SD=2.9)  G2: 2.3 (SD=2.9)  Within group change at post-treatment:  G1: -1.6 (calculated)  G2: 0.2 (calculated)  Between group change at post-treatment: -1.8 (calculated)  Between group ANOVA: F=18.66, df=1,106, p<0.001 |
| Goenjian, 1997; 20058, 9  NA; NA | CPTSD-RI (range: 0-80), Mean8a. Pretreatment  G1: 45.3 (SD=11.0) G2: 41.1 (SD=9.0) Within group change at 1.5 years:  G1: -13.1 (calculated)  G2: 6.1 (calculated)  Between group change at 1.5 years: -19.2 (calculated)  Adjusted between group MANOVA treatment\*time: F=31.16, df=1,56, p<0.05 Within group change at 3.5 years:  G1: -16.3 (SD=13.0)  G2: -5.4 (SD=11.0)  Between group change at 3.5 years: -10.9 (calculated)  Reported t-test between group difference: t=3.5, df=61, p<0.001 | NR | NA | DSRS (range: 0-63), Depression  Pretreatment  G1: 16.8 (SD=5.9) G2: 15.3 (SD=5.5) Within group change at 1.5 years:  G1: -0.8 (calculated)  G2: 4.9 (calculated)  Between group change at 1.5 years  G1 vs. G2: -5.7 (calculated)  Between group difference p value not reported  Within group change at 3.5 years:  G1: -1.7 (SD=5.4)  G2: 2.7 (SD=6.7)  Between group change at 3.5 years: -4.4 (calculated)  Reported t-test between group difference: t=2.9, df=61, p<0.01 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Jaycox, 200910  SSET | NA | NA | CPSS (range: NR), Mean Pretreatment:  G1: 17.46 (SD=10.37)  G2: 19.41 (SD=10.00) Within group change at post-treatment assessment:  G1: -3.74 (calculated), d=-0.39  G2: -1.09 (calculated), d=-0.16  Between group change at post-treatment assessment: -2.65 (calculated); d=-0.23; regression estimate for followup controlling for baseline=0.58, t=-1.89, p=0.058; fixed effects model adjusted for school and group leader found that estimates "remained stable" | CDI (range: NR), Mean Pretreatment:  G1: 13.87 (SD=8.52) G2: 14.32 (SD=9.20) Within group change at post-treatment assessment:  G1: -2.10 (calculated); d=-0.25  G2: 0.60 (calculated) d=0.07  Between group change at post-treatment assessment:-2.70 (calculated); d= -0.32; regression estimate of followup controlling for baseline=0.65, t=-1.99, p=0.046; fixed effects model adjusted for school and group leader found that estimates “remained stable” |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Kemp, 201011  NA | NA | Meeting two or more PTSD (DSM-IV) diagnostic criteria based on systematic clinical assessment  Pretreatment  G1: 100%  G2: 100%  Within group change in proportion at post-treatment:  G1: -75%  G2: 0%  Between group change at post-treatment:  -75% (calculated)  Χ2 (1, n=24)=14.40, p<0.001) | PTSD-RI symptoms  Pretreatment  G1: 25.92 (SD=12.18) G2: 27.29 (SD=12.58)  Magnitude of effect not specified by intervention type.  MANCOVA controlling for group differences at pretreatment for number of DSM-IV PTSD criteria and Child PTS-RI scores F(2, 17)=9.32, p<0.01  A priori contrasts identified a significant pre to post reduction in the number of DSM-IV PTSD  criteria [t(11)=4.17, p<0.01] and Child PTS-RI scores [t(11)=4.26, p=0.001] for G1 but not for G2 | STAIC – State Anxiety (range: 20-60), Mean  Pretreatment  G1: 28.50 (SD=4.68)  G2: 32.33 (SD=8.37)  Within group change:  G1: 0.33 (calculated)  G2: -0.66 (calculated)  Between group change (95% CI): 0.99 (calculated) p=NS  STAIC-Trait Anxiety (range: 20-60)  Pretreatment  G1: 35.42 (SD=7.51)  G2: 39.58 (SD=7.23)  Within group change:  G1: -1.92 (calculated)  G2: -3.41(calculated)  Between group change (95% CI): 1.49 (calculated) p=NS  CDS-Depression (range: 66-330)  Pretreatment  G1: 138.42 (SD=24.72)  G2: 137.50 (SD=27.87)  Within group change:  G1: -2.67 (calculated)  G2: -6.25 (calculated)  Between group change (95% CI): 3.58 (calculated) p=NS |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Layne, 200812  TGCT | NA | NR | UCLA-PTSD-RI-R (range: 0-68)  Pretreatment  G1: 36.37 (SD=14.27)  G2: 33.02 (SD=10.27)  Within group change:  G1 (95% CI): -11.85 (-15.28, -8.42)  G2 (95% CI): -5.67 (-8.93, -2.42)  Between group difference: -6.18 (calculated)  MANOVA between group time\*treatment group interaction F=6.77, df=1,125, p=0.01 | DSRS (range: 0-72)c.,  Pretreatment  G1: 32.61 (SD=11.39)  G2: 28.61 (SD=9.86)  Within group change:  G1 (95% CI): -2.69 (-5.33, -0.06)  G2 (95% CI): 1.91 (-0.68, 4.51)  Between group difference: -2.78 (calculated)  MANOVA between group time\*treatment group interaction F=6.16, df=1,125, p<0.05 |
| Nugent, 201013  NA | CAPS-CA (range: NR)d. No means reported.  Between group differences at followup not reported. Intent-to-treat linear regression predicting PTSD symptoms at post-treatment, adjusted for sex, age, and prior trauma PTSD severity, showed treatment group OR (95% CI)=1.32 (0.84, 2.08) (calculated) | CAPS-CAd. Diagnosis  No data reported for PTSD diagnosis other than X2<1; p=NS for G1 vs. G2 at post-treatment | NA | NR |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Robbe, 201014  NA | NA | NR | UCLA PTSD-RI-R (range: 0-68) Pretreatment  G1: 43.8 (SD=8.5)  G2: 42.1 (SD=8.8)  Within group LS mean change LOCF:  G1: -20.4 (SD=2.1)  G2: -22.8 (SD=2.1)  Between group LS mean change score difference LOCF 95% CI: -7.6, 2.9, p=0.373  CSDC, parent-rated (range: 0-30)  Pretreatment  G1: 33.5 (SD=10.5)  G2: 34.1 (SD=10.4)  Within group LS mean change LOCF:  G1: -12.4 (SD=1.7)  G2: -17.3 (SD=1.9)  Between group LS mean change score difference LOCF 95% CI: -9.1, -0.6, p=0.025  CGI-S, clinician-rated (range: 0-7) Pretreatment  G1: 4.5 (SD=0.6)  G2: 4.4 (SD=0.6)  Within group LS mean change LOCF:  G1: -1.4 (SD=0.2)  G2: -1.8 (SD=0.2)  Between group LS mean change score difference LOCF 95% CI: -0.8, 0.0, p=0.031  CGI-I, clinician-rated symptom improvement (range: 0-7)  Pretreatment  G1: NA  G2: NA  Within group LS mean change LOCF:  G1: 2.4 (SD=0.2)  G2: 2.2 (SD=0.2)  Between group LS mean change score difference LOCF 95% CI: -0.6, 0.3, p=0.415 | CDRS-R (range: 0-17), Mean Pretreatment  G1: 40.3 (SD=14.4)  G2: 41.2 (SD=14.2)  Within group LS mean change LOCF:  G1: -10.0 (SD=1.5)  G2: -12.3 (SD=1.6)  Between group LS mean change score difference LOCF 95% CI: -6.0,1.3, p=0.210 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Robertf, 199915  NA | NA | ASD symptom responders  G1: 83%  G2: 38%  Between-group difference in relieving ASD symptoms, X²=5.24, df=1, p=0.04 | NR | NR |
| Robertg, 200816  NA | NA | ASD Checklist  % responders at post-treatment:  G1: 60.0%  G2: 72.2%  G3: 54.5%  Between group difference in % responders at post-treatment p=NS | ASD Checklist, Mean  Pretreatment  G1: 42.6 (SD=12.4)  G2: 47.6 (SD=15.0)  G3: 44.6 (SD=14.0)  Within group % change in mean score post-treatment  G1: -62.6% (SD 39.5)  G2: -73.6% (SD 40.4)  G3: -65.1% (SD 41.5)  Between group difference in % change in mean score post-treatment: p=NS | NR |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Salloumh., 200817  NA | NA | NR | UPID-PTSD Symptoms (range: 0-80)  Pretreatment  G1: 28.28 (SD=13.61) G2: 31.32 (SD=12.43)  Post-treatment G1: 44.03 (SD=13.03) G2: 42.32 (SD=9.58) Within group change at post-treatment assessment:  G1: -15.75 (calculated)  G2: -11.00 (calculated)  Within group change in proportion at 20 day followup:  G1: -21.60 (calculated)  G2: -20.47 (calculated)  Between group change at post-treatment assessment:  -4.75 (calculated)  Intent-to-treat analyses effect size: 0.95  Between group change at 6 Mos. assessment: -1.13 (calculated)  Intent-to-treat analyses effect size: 1.34  General linear modeling repeated measure procedure time\*treatment interaction p=NS | MFQ-C, Mean Pretreatment  G1: 25.48 (SD=9.17) G2: 23.41 (SD=9.58) Within group change at post-treatment assessment:  G1: -8.57 (calculated)  G2: -2.95 (calculated)  Within group change in proportion at 20 day followup:  G1: -12.48 (calculated)  G2: -9.18 (calculated)  Between group change at post-treatment assessment: -5.62 (calculated)  Intent-to-treat analyses effect size: 0.47  Between group change at 6 Mos. assessment: -3.30 (calculated)  Intent-to-treat analyses effect size: 0.92  General linear modeling repeated measure procedure time\*treatment interaction p=NS |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Salloum, 201218 NA | NA | UCLA PTSD-I of 38+ (clinically significant PTSD)  Pretreatment:  G1: 46.2%  G2: 39.4%  Within group change at 12 Mos. assessment:  G1: -40.3%  G2: -29.4%  Between group change at 12 Mos. assessment: -10.9%, p=NR | UCLA-PTSD-I (range: NR) Pretreatment: G1: 46.82 (SD=13.00) G2: 42.80 (SD=10.77) Within group change at post-treatment assessment:  G1: -15.64, d=0.92, p=NR G2: -15.23, d=0.78, p=NR  Between group change at post-treatment assessment: -0.41, p=NR Within group change at 3 Mos. assessment:  G1: -16.94, d=1.06, p=NR G2: -16.5, d=0.78, p=NR Between group change at 3 Mos. assessment: -0.44, p=NR Within group change at 12 Mos. assessment:  G1: -22.08, d=1.83, p=NR; (RCI: 70.59% improved, 2.94% deteriorated) G2: -17.27, d=1.50, p=NR (RCI: 60% improved, 3.33% deteriorated) Between group change at 12 Mos. assessment: -4.81, ANOVA time\*treatment interaction p=NS; RCI difference p=NS | MFQ-C of 29+ (clinically significant depression)  Pretreatment:  G1: 43.6%  G2: 27.3%  Within group change at 12 Mos. assessment:  G1: -43.6%  G2: -20.8%  Between group change at 12 Mos. assessment: -22.8%, p=NR  MFQ-C (range: NR) Pretreatment: G1: 27.62 (SD=10.18) G2: 22.83 (SD=8.65) Within group change at post-treatment assessment:  G1: -9.12, d=0.91, p=NR G2: -9.00, d=0.99, p=NR Between group change at post-treatment assessment: -0.12, p=NR Within group change at 3 Mos. assessment:  G1: -9.18, d=0.87, p=NR G2: -8.00, d=0.85, p=NR Between group change at 3 Mos. assessment: -1.18, p=NR Within group change at 12 Mos. assessment: G1: -13.94, d=1.43, p=NR (RCI: 52.9% improved, 0% deteriorated) G2: -9.00, d=0.97, p=NR (RCI: 43.33% improved, 3.33% deteriorated) Between group change at 12 Mos. assessment: -4.94, ANOVA time\*treatment interaction p=NR; RCI difference p=NS EGI (range: NR) Pretreatment: G1: 53.03 (SD=17.75) G2: 46.00 (SD=21.83) |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Salloum, 201218 NA |  |  |  | Within group change at post-treatment assessment:  G1: -16.90, d=0.92, p=NR  G2: -16.69, d=0.78, p=NR Between group change at post-treatment assessment: -0.39, p=NR Within group change at 3 Mos. assessment:  G1: -19.62, d=0.96, p=NR G2: -16.62, d=1.18, p=NR Between group change at 3 Mos. assessment: -3.00, p=NR Within group change at 12 Mos. assessment: G1: -26.72, d=1.61, p=NR (RCI: 68.75% improved, 0% deteriorated) G2: -19.00, d=0.91, p=NR (RCI: 55.17% improved, 3.45% deteriorated) Between group change at 12 Mos. assessment: -7.72, ANOVA time\*treatment interaction p=NR; RCI difference p=NS GD (range: NR) Pretreatment: G1: 2.71 (SD=1.32) G2: 2.72 (SD=1.13) Within group change at post-treatment assessment:  G1: -0.80, d=0.60, p=NR G2: -1.03, d=0.86, p=NR  Between group change at post-treatment assessment: 0.23, p=NR Within group change at 3 Mos. assessment:  G1: -1.36, d=1.06, p=NR G2: -1.34, d=0.78, p=NR Between group change at 3 Mos. assessment: -0.02, p=NR  Within group change at 12 Mos. assessment:  G1: -1.53, d=1.19, p=NR G2: -1.24, d=1.06, p=NR  Between group change at 12 Mos. assessment: -0.29, ANOVA time\*treatment interaction p=NR |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Smith, 200719  NA | NA | ADIS-C/P PTSD Diagnosis (range: NR)  Pretreatment  G1: 100%  G2: 100%  Within group change in proportions at post-treatment:  G1: -92%  G2: -42%  Between group change in proportions at post-treatment:  -50% (calculated)  X²=6.8, df=1, 24, p<0.01 | CPSS Symptoms (range: NR)  Pretreatment  G1: 28.1 (SD=8.8)  G2: 28.3 (SD=10.5)  Within group change at post-treatment:  G1: -25.1 (calculated)  G2: -3.05 (calculated)  Between group change at post-treatment: -22.05 (calculated)  MANCOVA F=48.3, df=1,18, p<0.001  C-RIES Symptoms (range: NR)  Pretreatment  G1: 47.5 (SD=11.5)  G2: 41.6 (SD=11.7)  Within group change at post-treatment:  G1: -39.0 (calculated)  G2: -6.3 (calculated)  Between group change at post-treatment: -32.7 (calculated) MANCOVA F=36.8, df=1,18, p<0.001  CAPS symptoms (range: NR)  Pretreatment  G1: 60.9 (SD=9.6)  G2: 54.7 (SD=14.6)  Within group change at post-treatment:  G1: -48.9 (calculated)  G2: -14.4 (calculated)  Between group change at post-treatment: -34.5 (calculated) MANCOVA F=20.2, df=1,18, p<0.005 | DSRS Depression (range: NR)  Pretreatment  G1: 18.3 (SD=5.2)  G2: 13.9 (SD=5.6)  Within group change at post-treatment:  G1: -10.3 (calculated)  G2: -0.6 (calculated)  Between group change at post-treatment: -9.7 (calculated) MANCOVA F=19.1, df=1,18, p<0.001  RCMAS Anxiety (range: NR)  Pretreatment  G1: 19.8 (SD=5.6)  G2: 16.3 (SD=5.7)  Within group change at post-treatment:  G1: -12.4 (calculated)  G2: 0.2 (calculated)  Between group change at post-treatment:  -12.6 (calculated) MANCOVA F=14.3, df=1,18, p<0.005 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Stein, 200320  NA | NA | NA | CPSS symptoms (range: 0-51)  Pretreatment  G1: 24.5 (6.8)  G2: 23.5 (7.2)  Within group change:  G1: -15.6 (calculated)  G2: -8.0 (calculated)  Adjusted between group change (95% CI): -7.0 (-10.8, -3.2) | CDI Depression (range: 0-52)  Difference  Pretreatment  G1: 17.6 (10.8)  G2: 16.7 (7.3)  Within group change:  G1: -8.2 (calculated)  G2: -4.0 (calculated)  Adjusted between group change (95% CI): -3.4 (-6.5, -0.4) |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Tol, 2008; 201021, 22  NA; NA | NA | NR | CPSS (range: 0-68)  Pretreatment  G1: 20.92 (SD=8.75)  G2: 22.35 (SD=8.39)  Within group change at 1 week:  G1: -9.10 (SD=9.20)  G2: -4.85 (SD=9.49)  Within group change at 6 Mos.:  G1: -10.35 (SD=8.89)  G2: -6.15 (SD=10.04)  Between group difference at 1 week (95% CI): d=0.55 (0.35, 0.75)  Between group difference at 6 Mos.:  Mixed method regression analysis mean change difference adjusted for school mean (95% CI): 2.78 (1.02, 4.53), d=0.44 (0.24, 0.64) | DSRS depression (range: 0-36)  Pretreatment  G1: 12.29 (SD=3.33)  G2: 12.55 (SD=3.47)  Within group change at 1 week:  G1: -0.80 (SD=3.88)  G2: 0.50 (SD=4.33)  Within group change at 6 Mos.:  G1: -0.82 (SD=3.82)  G2: 0.16 (SD=4.73)  Between group difference at 1 week (95% CI): d=0.31 (0.12, 0.51)  Between group difference at 6 Mos.:  Mixed method regression analysis mean change difference adjusted for school mean (95% CI): -0.70 (-0.08, 1.49), d= 0.24 (0.04, 0.43) SCARED-5 anxiety (range: 0-10)  Pretreatment  G1: 4.38 (SD=1.76)  G2: 4.46 (SD=1.87)  Within group change at 1 week:  G1: -0.97 (SD=2.16)  G2: -0.65 (SD=2.32)  Within group change at 6 Mos.:  G1: -1.06 (SD=2.45)  G2: -0.96 (SD=2.49)  Between group difference at 1 week (95% CI): d=0.14 (-0.05, 0.34)  Between group difference at 6 Mos.:  Mixed method regression analysis mean change difference adjusted for school mean (95% CI): -0.12 (-0.31, 0.56), d=0.04 (-0.16, 0.24) |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Tol, 201223  NA | NA | NA | CPSS (range: 0-51), PTSD symptoms: Pretreatment  G1: 15.03 (SD=8.89) G2: 15.70 (SD=9.12) Within group change at post-treatment assessment: G1: NR G2: NR Between group change at post-treatment assessment: NR LGCM estimate (SE): 0.281 (0.332); p=NS | DSRS (range: 0-36), Depressive symptoms: Pretreatment  G1: 8.39 (SD=4.54) G2: 8.56 (SD=4.37) Within group change at post-treatment assessment: G1: NR G2: NR Between group change at post-treatment assessment: NR LGCM estimate (SE): 0.115 (0.112); p=NS SCARED-5 (range 0-10), Anxiety symptoms: Pretreatment  G1: 3.29 (SD=2.13) G2: 3.17 (SD=2.16) Within group change at post-treatment assessment: G1: NR G2: NR Between group change at post-treatment assessment: NR LGCM estimate (SE): -0.037 (0.065); p=NS SDQ (range: 0-40), Psychological difficulties: Pretreatment  G1: 10.74 (SD=5.57) G2: 10.29 (SD=5.44) Within group change at post-treatment assessment: G1: NR G2: NR Between group change at post-treatment assessment: NR LGCM estimate (SE): -0.198 (0.280); p=NS |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author,  Year,  Trial Name | Prevention of Traumatic Stress Symptoms or Syndromes | Remission of PTSD | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms |
| Tol, 201223  NA |  |  |  | Supernatural complaints (range: 0-18): Pretreatment  G1: 2.21 (SD=2.59) G2: 1.97 (SD=1.92) Within group change at post-treatment assessment: G1: NR G2: NR Between group change at post-treatment assessment: NR LGCM estimate (SE): -0.121 (0.064); p<0.06 |
| Zehnder, 201024  NA | IBS-K (range: NR), Mean Pretreatment:  G1: 29.3 (SD=23.7)  G2: 26.3 (SD=23.0)  Within group change at Time 1 assessment:  G1: -7.7 (calculated)  G2: -7.8 (calculated)  Between group change at Time 1 assessment: 0.1 (calculated)  Within group change at Time 2 assessment:  G1: -5.7 (calculated)  G2: -4.4; (calculated) Between group change at Time 2 assessment: -1.3 (calculated)  Repeated measures ANOVA treatment\*time interaction: F=0.10, p=NS | NA | NA | DIKJ (range: NR), Mean Pretreatment:  G1: 10.1 (SD=6.0)  G2: 9.6 (SD=6.5)  Within group change at Time 1 assessment:  G1: -1.9 (calculated)  G2: -1.0 (calculated)  Between group change at Time 1 assessment: -0.9 (calculated)  Within group change at Time 2 assessment:  G1: -1.0 (calculated)  G2: -0.9 (calculated)  Between group change at Time 2 assessment -0.1 (calculated)  Repeated measures ANOVA treatment\*time interaction: F=0.01, p=NS |

a. 18 month data reported in #840 differs slightly from that reported in #1589.

b. Post-Tx results and mean change only reported in figure.

c. Also conducted 4 month follow-up on PTSD, Depression, and Grief Reactions. These analyses were only done on those who had pre, post, and 4-month follow-up data (not ITT analysis).

d. Girls receiving propranolol reported more PTSD symptoms relative to girls receiving placebo. Boys receiving propranolol showed a nonsignificant trend toward fewer PTSD symptoms than boys receiving placebo.

e. Sertraline did not demonstrate efficacy compared with placebo.

f. No standardized scales used.

g. Placebo was statistically as effective as either Imipramine or Fluoxetine in treating symptoms of ASD.

h. Treatment satisfaction 1: "I learned more about grief and trauma reactions" (1-10, with 10 being highest); mean score at follow-up: 9.20. Treatment satisfaction 2: "I expressed my thoughts and feelings about what happened"; mean score at follow-up: 9.18. Treatment satisfaction 3: "On a scale from 1 to 10, how helpful was counseling for you?"; mean score at follow-up: 9.31.

i. Debriefing was no more effective than placebo group intervention, although both groups made significant improvements in PTSD symptoms.

Abbreviations: ADIS-C/P = Anxiety Disorders Interview Schedule; ASD = Acute Stress Disorder; BDI = Beck Depression Inventory; CAPS-CA = Clinician-Administered Post-Traumatic Stress Disorder Scale For Children And Adolescents; CDI = Child Depression Inventory; CDRS-R = Children’s Depression Rating Scale-Revised; CDS = Children’s Depression Scale; CGI-I = Clinical Global Impressions-Improvement Scale; CGI-S = Clinical Global Impressions – Severity Scale; CI = confidence interval; CPSS = Child PTSD Symptom Scale; CPTSD-RI = Child Post-Traumatic Stress Reaction Index; C-RIES = Children’s Revised Impact of Event Scale; CSDC = Child Stress Disorder Checklist; d = effect size; df = degrees of freedom; DIKJ = German Version of CDI; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSRS = Depression Self-Rating Scale; Dx = diagnosis; EGI = Extended Grief Inventory; ERASE-Stress – Enhancing Resilience among Students Experiencing Stress; ES-SL = ERASE Stress Sri Lanka; G = group; GD = Global Distress; IBS-K = German Version of CAPS-CA; IES = Impact of Events Scale; LGCM = latent growth curve modeling; LOCF = last observation carried forward; LS = least-squares; MFQ-C = Mood and Feeling Questionnaire – Child Version; Mos. = months; N = number; NA = not applicable; NR = not reported; NS = not significant; OR = odds ratio; PSS-SR = Post-Traumatic Stress Disorder Symptom Scale Self Report; PTCI = Post-Traumatic Cognitions Inventory; PTSD = Posttraumatic Stress Disorder; RCI = Reliable Change Index; RCMAS = Revised Children’s Manifest Anxiety Scale; SCARED = Screen for Child Anxiety Related Emotional Disorders; SCARED-5 = Self-Report for Anxiety-Related Disorders; SD = standard deviation; SDQ = Strengths and Difficulties Questionnaire; SE = standard error; SSET = Support for Students Exposed to Trauma; STAIC – State Trait Anxiety Inventory for Children; TARGET = Trauma Affect Regulation: Guide for Education and Therapy; TGCT = Trauma and Grief Component Therapy; TSCC = Trauma Symptom Checklist for Children; UCLA PTSD-I = University of California, Los Angeles Post-Traumatic Stress Disorder Index; UCLA-PTSD-RI-R = University of California, Los Angeles Post-Traumatic Stress Disorder Reaction Index, Revised; UCLA PTSD-Symptom Severity = University of California, Los Angeles Post-Traumatic Stress Disorder – Symptom Severity; UPID = University of California, Los Angeles Index for DSM-IV for children.